Europe Pharmaceutical Contract Development and Manufacturing Market
Added: (Mon Sep 04 2023)
Pressbox (Press Release) -
According to this latest publication from Meticulous Researchฎ, the europe pharmaceutical contract development and manufacturing market is expected to reach $68.12 billion by 2030 at a CAGR of 7.4% from 2023 to 2030. The growth of the Europe pharmaceutical contract development and manufacturing market is attributed to the rising incidence & prevalence of chronic illness, rising awareness of overall health and treatment availability, growing geriatric population in the region, rising pharmaceutical R&D expenditure, low-cost manufacturing advantages, increasing government funding for drug development and research, improving healthcare infrastructure, and growing healthcare spending.
The lack of skilled professionals is challenging the growth of this market. High demand for personalized medicine, cell therapies, and gene therapies, and growth in high potency Active Pharmaceutical Ingredients (HPAPI) and Antibody-drug Conjugates (ADC) market in European countries are providing opportunities for market growth.
Download Free PDF Sample Copy of the Report (with COVID-19 Impact Analysis): https://www.meticulousresearch.com/download-sample-report/cp_id=5592
Scope of the Report:
Europe Pharmaceutical Contract Development and Manufacturing Market Assessment, by Type
Pharmaceutical Manufacturing Services
o Active Pharmaceutical Ingredient (API) Manufacturing Services
o Finished Dosage Forms (FDF) Manufacturing Services
Parenteral/Injectable Manufacturing Services
Tablet Manufacturing Services
Capsule Manufacturing Services
Oral Liquid Manufacturing Services
Other Formulations
Drug Development Services
Biologics Manufacturing Services
o Active Pharmaceutical Ingredient (API) Manufacturing Services
o Finished Dosage Forms (FDF) Manufacturing Services
(Note:Other formulations include topical formulations, powders formulations, and modified-release dosage forms)
Europe Pharmaceutical Contract Development and Manufacturing Market Assessment, by End User
Large Pharmaceutical Companies
Small & Mid-Size Pharmaceutical Companies
Generic Pharmaceutical Companies
Europe Pharmaceutical Contract Development and Manufacturing Market Assessment, by Country
Germany
U.K.
France
Italy
Spain
Switzerland
Netherlands
Denmark
Rest of Europe
To Gain More Insights into the Market with a Detailed Table of Content and Figures, Click Here: https://www.meticulousresearch.com/product/europe-pharmaceutical-contract-development-and-manufacturing-market-5592
Key Players
The key players operating in the Europe pharmaceutical contract development and manufacturing market are AbbVie Inc. (U.S.), Aenova Group (Germany), Wuxi Biologics, Inc. (China), Vetter Pharma International GmbH (Germany), Catalent, Inc. (U.S.), Lonza Group Ltd. (Switzerland), Recipharm AB (Sweden), Almac Group (U.K.), C.H. Boehringer Sohn Ag & Co. KG. (Germany), Eurofins Scientific (France), Curia Global, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Evonik Industries AG (Germany), Cambrex Corporation (U.S.), Siegfried Holdings AG (Switzerland), Fabbrica Italiana Sintetici S.p.A. (Italy), and Corden Pharma GmbH (Germany).
Europe Pharmaceutical Contract Development and Manufacturing Market: Future Outlook
The Europe pharmaceutical contract development and manufacturing market is segmented by Type (Pharmaceutical Manufacturing Services {Active Pharmaceutical ingredient (API) Manufacturing Services and Finished Dosage Forms (FDF) Manufacturing Services [Parenteral/Injectable Manufacturing Services, Tablet Manufacturing Services, Capsule Manufacturing Services, Oral Liquid Manufacturing Services, and Other Formulations]}, Drug Development Services, and Biologics Manufacturing Services{Active Pharmaceutical ingredient (API) Manufacturing Services and Finished Dosage Forms (FDF) Manufacturing Services}), End User (Large Pharmaceutical Companies, Small & Mid-Size Pharmaceutical Companies, and Generic Pharmaceutical Companies), and Countries. The study also evaluates industry competitors and analyzes their market share at the country level.
Request Customization Here: https://www.meticulousresearch.com/request-customization/cp_id=5592
Among all types studied in this report, in 2023, the pharmaceutical manufacturing services segment is expected to account for the largest share of the Europe pharmaceutical contract development and manufacturing market. The pharmaceutical manufacturing services segment is further segmented into active pharmaceutical ingredient (API) manufacturing services and finished dosage forms (FDF) manufacturing services. The largest share of this segment is attributed to the need to reduce manufacturing costs, to bring a new drug to the market quickly at the lowest possible cost, the requirement for high-quality bulk manufacturing, and the growing demand for generic drugs.
Among all end users studied in this report, the generic pharmaceutical companies segment is expected to register the highest CAGR over the forecast period. The growth of this end-user segment is driven by the increasing competition in the generic market leading to pricing pressure and the growing inclination of these companies toward the use of cutting-edge technologies offered by contract development and manufacturing firms.